Metoprolol withdrawal symptoms
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Withdrawal Symptoms: An Overview
Introduction to Metoprolol Withdrawal
Metoprolol, a beta-blocker commonly prescribed for hypertension and heart conditions, can lead to withdrawal symptoms when discontinued. Understanding these symptoms is crucial for managing patient care effectively.
Rebound Increase in Heart Rate and Cardiac Sensitivity
One of the most notable withdrawal symptoms of metoprolol is a rebound increase in heart rate and cardiac sensitivity. Studies have shown that abrupt withdrawal can lead to a significant rise in resting heart rate and increased sensitivity to isoproterenol, a medication that stimulates the heart1 5 7. This rebound effect typically occurs within the first week after discontinuation and can persist for several days1 5.
Mental and Cardiac Symptoms
Patients withdrawing from metoprolol may experience a range of mental and cardiac symptoms. Increased mental stress and cardiac symptoms such as palpitations and chest pain have been reported more frequently in patients who discontinued metoprolol compared to those who continued the medication2 4. These symptoms can be severe enough to necessitate the reinstitution of treatment in some cases2.
Blood Pressure and Arrhythmias
While a transient increase in blood pressure has been observed in some patients following metoprolol withdrawal, it is generally less common compared to the rebound in heart rate1 5. Additionally, there is an increased risk of arrhythmias, particularly during periods of mental stress, although this risk tends to normalize over time4.
Impact on Left Ventricular Function
Withdrawal of metoprolol can also affect left ventricular function. Studies have shown that heart rate increases significantly after withdrawal, leading to changes in cardiac cycle intervals and potentially impacting overall cardiac function3. This can be particularly concerning for patients with pre-existing heart conditions.
Plasma Catecholamine Levels
Changes in plasma catecholamine levels, such as norepinephrine and epinephrine, have been observed during metoprolol withdrawal. These changes are indicative of increased beta-adrenoceptor responsiveness, which may contribute to the clinical symptoms experienced during withdrawal2 4.
Prevention and Management of Withdrawal Symptoms
Gradual tapering of metoprolol, rather than abrupt discontinuation, can help mitigate withdrawal symptoms. Studies have shown that a prolonged low-dose withdrawal schedule can significantly reduce, though not completely prevent, the rebound effects on heart rate and cardiac sensitivity1 5. Continuous monitoring and appropriate management strategies are essential to minimize adverse effects during the withdrawal period.
Conclusion
Metoprolol withdrawal can lead to a range of symptoms, including increased heart rate, mental stress, and changes in cardiac function. Gradual tapering and careful monitoring are crucial to managing these symptoms effectively. Understanding the mechanisms and potential risks associated with metoprolol withdrawal can help healthcare providers better support their patients during this transition.
Sources and full results
Most relevant research papers on this topic
Metoprolol withdrawal phenomena: Mechanism and prevention
Abrupt metoprolol withdrawal leads to a rebound increase in cardiac beta-adrenergic sensitivity, potentially impacting the mechanism and prevention of beta-blocker syndrome in patients with angina.
Non-RCTRebound phenomena following gradual withdrawal of chronic metoprolol treatment in patients with ischemic heart disease.
Gradual withdrawal of metoprolol treatment in patients with ischemic heart disease can lead to rebound increases in heart rate and mental symptoms, with some patients needing reinstitution of treatment.
RCTLeft ventricular function following withdrawal of chronic metoprolol treatment in patients with ischaemic heart disease. A double blind study.
Gradual withdrawal of chronic metoprolol treatment in postinfarction patients leads to increased heart rate and prolongation of pre-ejection period, but no significant change in left ventricular function.
RCTCardiovascular reactivity to mental stress during gradual withdrawal of chronic postinfarction treatment with metoprolol.
Gradual withdrawal of metoprolol from postinfarction patients does not cause a rebound increase in cardiovascular reactivity to mental stress, suggesting slow recovery of central cardiovascular control mechanisms.
RCTComparison of withdrawal phenomena after propranolol, metoprolol and pindolol.
Abrupt withdrawal from propranolol, metoprolol, and pindolol can cause rebound cardiac sensitivity, resting heart rate, and blood pressure changes, with gradual withdrawal preventing these effects.
Observational Study
Highly CitedLong-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.
Long-term metoprolol treatment improves heart function and reduces symptoms in patients with dilated cardiomyopathy, but may cause heart rate and left atrial dimension changes when withdrawn.
Non-RCTHighly CitedComparison of withdrawal phenomena after propranolol, metoprolol, and pindolol.
Withdrawal symptoms of headache, palpitations, and tremor occurred after propranolol and metoprolol, but not after pindolol, suggesting drug potency.
RCTLong‐Term Metoprolol Therapy and Neuroleptanesthesia in Coronary Artery Surgery: Withdrawal versus Maintenance β1–Adrenoreceptor Blockade
Preoperative metoprolol withdrawal may precipitate myocardial ischemia, while maintaining therapy is well tolerated and may prevent complications.
RCTMetoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group.
Metoprolol effectively reduces heart rate and blood pressure in acute myocardial infarction patients, but may cause more side effects and temporary withdrawal of trial medication.
RCTPrognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up.
Continuous postinfarction beta blocker therapy is beneficial, but digitalis therapy may negatively impact survival during long-term follow-up.
RCT
Large Human Trial